Literature DB >> 23242100

Combination antifungal therapy for invasive pulmonary aspergillosis.

Salman Abdulaziz1, Hamdan Al Jahdali, Salim Baharoon.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242100      PMCID: PMC4544971          DOI: 10.1136/bcr-2012-007824

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


× No keyword cloud information.
  5 in total

1.  Case collection study of the safety of AmBisome in association with voriconazole in the treatment of patients with invasive fungal infection.

Authors:  Elham Askari; Isidro Jarque; Silvestre Nicolás Franco; Juan José Cáceres Agra
Journal:  Rev Esp Quimioter       Date:  2010-12       Impact factor: 1.553

2.  Aspergillus fumigatus tricuspid native valve endocarditis in a non-intravenous drug user.

Authors:  Antonios Vassiloyanakopoulos; Matthew E Falagas; Maria Allamani; Argyris Michalopoulos
Journal:  J Med Microbiol       Date:  2006-05       Impact factor: 2.472

3.  Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans.

Authors:  Eriques Gonçalves Silva; Claudete Rodrigues Paula; Amanda Latercia Tranches Dias; Marilene Rodrigues Chang; Luciana da Silva Ruiz; Valderez Gambale; Renato Araujo Prates; Martha Simões Ribeiro
Journal:  Mycopathologia       Date:  2010-10-24       Impact factor: 2.574

Review 4.  Newer combination antifungal therapies for invasive aspergillosis.

Authors:  William J Steinbach; Praveen R Juvvadi; Jarrod R Fortwendel; Luise E Rogg
Journal:  Med Mycol       Date:  2010-07-07       Impact factor: 4.076

5.  Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro.

Authors:  M Scheven; F Schwegler
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

  5 in total
  1 in total

1.  Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.

Authors:  Maria Siopi; Nikolaos Siafakas; Sophia Vourli; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.